Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases

Y. Kanazawa, Y. Kaneshiro, M. Sawa, Hidekata Yasuoka, T. Nojima, Y. Ohosone, T. Mimori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Autoantibodies to calpastatin (endogenous inhibitor of calpain, a calcium-dependent neutral proteinase) have been detected in sera of patients with rheumatoid arthritis (RA) and other diseases. We investigated the epitope reactivity of anticalpastatin autoantibodies in patients with rheumatic diseases. cDNAs encoding each calpastatin domain (L, I, II, III, and IV) were amplified by PCR and ligated into an expression vector. The fusion proteins were expressed in E. coli. The presence of autoantibodies specific for each calpastatin domain was assayed in sera of patients with various rheumatic diseases by immunoblotting the fusion proteins with these sera. Of the RA patient sera, 81% reacted with at least one calpastatin domain. This reaction was significantly greater than with sera from patients with systemic lupus erythematosus (46%), scleroderma (32%), polymyositis/dermatomyositis (43%), and normal controls (13%). Domains I and II were recognized by RA patient sera significantly more than by other patient sera, whereas domains III and IV reacted almost equally among all patient sera. Although, collectively, sera from RA and lupus patients reacted equally with all domains, scleroderma sera tended to react with only domains I and IV and myositis sera tended to recognize only domains III and IV. Patients with RA positive for anticalpastatin antibodies exhibited more active disease (i.e., a higher erythrocyte sedimentation rate and C-reative protein level) than antibody-negative patients. Our results suggest that anticalpastatin antibodies were detected in RA with the highest frequency and that different domain reactivity was shown among different diseases. The presence of these antibodies in sera may be related to the type of disease and, in RA, with disease activity, suggesting their importance in rheumatic disorders.

Original languageEnglish
Pages (from-to)38-44
Number of pages7
JournalModern Rheumatology
Volume10
Issue number1
DOIs
Publication statusPublished - 2000 Jan 3

Fingerprint

Rheumatic Diseases
Autoantibodies
Rheumatoid Arthritis
Serum
Antibodies
calpastatin
Myositis
Calpain
Dermatomyositis
Blood Sedimentation
Protein C
Immunoblotting
Systemic Lupus Erythematosus
Blood Proteins
Epitopes
Complementary DNA
Escherichia coli
Polymerase Chain Reaction

Keywords

  • Autoantibody
  • Autoimmune disease
  • Calpain
  • Calpastatin
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Kanazawa, Y., Kaneshiro, Y., Sawa, M., Yasuoka, H., Nojima, T., Ohosone, Y., & Mimori, T. (2000). Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases. Modern Rheumatology, 10(1), 38-44. https://doi.org/10.3109/s101650070037

Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases. / Kanazawa, Y.; Kaneshiro, Y.; Sawa, M.; Yasuoka, Hidekata; Nojima, T.; Ohosone, Y.; Mimori, T.

In: Modern Rheumatology, Vol. 10, No. 1, 03.01.2000, p. 38-44.

Research output: Contribution to journalArticle

Kanazawa, Y, Kaneshiro, Y, Sawa, M, Yasuoka, H, Nojima, T, Ohosone, Y & Mimori, T 2000, 'Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases', Modern Rheumatology, vol. 10, no. 1, pp. 38-44. https://doi.org/10.3109/s101650070037
Kanazawa, Y. ; Kaneshiro, Y. ; Sawa, M. ; Yasuoka, Hidekata ; Nojima, T. ; Ohosone, Y. ; Mimori, T. / Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases. In: Modern Rheumatology. 2000 ; Vol. 10, No. 1. pp. 38-44.
@article{52a227dc34e54d6b819d98e7d137eb66,
title = "Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases",
abstract = "Autoantibodies to calpastatin (endogenous inhibitor of calpain, a calcium-dependent neutral proteinase) have been detected in sera of patients with rheumatoid arthritis (RA) and other diseases. We investigated the epitope reactivity of anticalpastatin autoantibodies in patients with rheumatic diseases. cDNAs encoding each calpastatin domain (L, I, II, III, and IV) were amplified by PCR and ligated into an expression vector. The fusion proteins were expressed in E. coli. The presence of autoantibodies specific for each calpastatin domain was assayed in sera of patients with various rheumatic diseases by immunoblotting the fusion proteins with these sera. Of the RA patient sera, 81{\%} reacted with at least one calpastatin domain. This reaction was significantly greater than with sera from patients with systemic lupus erythematosus (46{\%}), scleroderma (32{\%}), polymyositis/dermatomyositis (43{\%}), and normal controls (13{\%}). Domains I and II were recognized by RA patient sera significantly more than by other patient sera, whereas domains III and IV reacted almost equally among all patient sera. Although, collectively, sera from RA and lupus patients reacted equally with all domains, scleroderma sera tended to react with only domains I and IV and myositis sera tended to recognize only domains III and IV. Patients with RA positive for anticalpastatin antibodies exhibited more active disease (i.e., a higher erythrocyte sedimentation rate and C-reative protein level) than antibody-negative patients. Our results suggest that anticalpastatin antibodies were detected in RA with the highest frequency and that different domain reactivity was shown among different diseases. The presence of these antibodies in sera may be related to the type of disease and, in RA, with disease activity, suggesting their importance in rheumatic disorders.",
keywords = "Autoantibody, Autoimmune disease, Calpain, Calpastatin, Rheumatoid arthritis",
author = "Y. Kanazawa and Y. Kaneshiro and M. Sawa and Hidekata Yasuoka and T. Nojima and Y. Ohosone and T. Mimori",
year = "2000",
month = "1",
day = "3",
doi = "10.3109/s101650070037",
language = "English",
volume = "10",
pages = "38--44",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Domain reactivity of autoantibodies to calpastatin in patients with systemic rheumatic diseases

AU - Kanazawa, Y.

AU - Kaneshiro, Y.

AU - Sawa, M.

AU - Yasuoka, Hidekata

AU - Nojima, T.

AU - Ohosone, Y.

AU - Mimori, T.

PY - 2000/1/3

Y1 - 2000/1/3

N2 - Autoantibodies to calpastatin (endogenous inhibitor of calpain, a calcium-dependent neutral proteinase) have been detected in sera of patients with rheumatoid arthritis (RA) and other diseases. We investigated the epitope reactivity of anticalpastatin autoantibodies in patients with rheumatic diseases. cDNAs encoding each calpastatin domain (L, I, II, III, and IV) were amplified by PCR and ligated into an expression vector. The fusion proteins were expressed in E. coli. The presence of autoantibodies specific for each calpastatin domain was assayed in sera of patients with various rheumatic diseases by immunoblotting the fusion proteins with these sera. Of the RA patient sera, 81% reacted with at least one calpastatin domain. This reaction was significantly greater than with sera from patients with systemic lupus erythematosus (46%), scleroderma (32%), polymyositis/dermatomyositis (43%), and normal controls (13%). Domains I and II were recognized by RA patient sera significantly more than by other patient sera, whereas domains III and IV reacted almost equally among all patient sera. Although, collectively, sera from RA and lupus patients reacted equally with all domains, scleroderma sera tended to react with only domains I and IV and myositis sera tended to recognize only domains III and IV. Patients with RA positive for anticalpastatin antibodies exhibited more active disease (i.e., a higher erythrocyte sedimentation rate and C-reative protein level) than antibody-negative patients. Our results suggest that anticalpastatin antibodies were detected in RA with the highest frequency and that different domain reactivity was shown among different diseases. The presence of these antibodies in sera may be related to the type of disease and, in RA, with disease activity, suggesting their importance in rheumatic disorders.

AB - Autoantibodies to calpastatin (endogenous inhibitor of calpain, a calcium-dependent neutral proteinase) have been detected in sera of patients with rheumatoid arthritis (RA) and other diseases. We investigated the epitope reactivity of anticalpastatin autoantibodies in patients with rheumatic diseases. cDNAs encoding each calpastatin domain (L, I, II, III, and IV) were amplified by PCR and ligated into an expression vector. The fusion proteins were expressed in E. coli. The presence of autoantibodies specific for each calpastatin domain was assayed in sera of patients with various rheumatic diseases by immunoblotting the fusion proteins with these sera. Of the RA patient sera, 81% reacted with at least one calpastatin domain. This reaction was significantly greater than with sera from patients with systemic lupus erythematosus (46%), scleroderma (32%), polymyositis/dermatomyositis (43%), and normal controls (13%). Domains I and II were recognized by RA patient sera significantly more than by other patient sera, whereas domains III and IV reacted almost equally among all patient sera. Although, collectively, sera from RA and lupus patients reacted equally with all domains, scleroderma sera tended to react with only domains I and IV and myositis sera tended to recognize only domains III and IV. Patients with RA positive for anticalpastatin antibodies exhibited more active disease (i.e., a higher erythrocyte sedimentation rate and C-reative protein level) than antibody-negative patients. Our results suggest that anticalpastatin antibodies were detected in RA with the highest frequency and that different domain reactivity was shown among different diseases. The presence of these antibodies in sera may be related to the type of disease and, in RA, with disease activity, suggesting their importance in rheumatic disorders.

KW - Autoantibody

KW - Autoimmune disease

KW - Calpain

KW - Calpastatin

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0346758034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346758034&partnerID=8YFLogxK

U2 - 10.3109/s101650070037

DO - 10.3109/s101650070037

M3 - Article

AN - SCOPUS:0346758034

VL - 10

SP - 38

EP - 44

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -